Výsledky vyhledávání

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

Autor: Dong-Wook Kim, Jodi Prime, Ju Hee Bang, Jin Eok Park, Soo Young Choi, David M. Ross, Timothy P. Hughes, David T Yeung, Susan Branford

Publikováno v: Blood. 119:4264-4271

Rising BCR-ABL1 transcripts indicate potential loss of imatinib response in CML. We determined whether the BCR-ABL1 doubling time could distinguish nonadherence from resistance as the cause of lost response. Distinct groups were examined: (1) acquire

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f06a66db492859f4c1ee54b652dd37b
https://doi.org/10.1182/blood-2011-11-393041

Zobrazit plný text záznamu

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

Autor: Deborah L. White, Timothy P. Hughes, Dale B. Watkins, Sarah Moore, Carine Tang, Wendy T Parker, Lisa Schafranek, Jodi Prime

Publikováno v: Leukemia & Lymphoma. 52:2139-2147

There are three currently identified secondary resistance mechanisms observed in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs). These are BCR-ABL kinase domain (KD) mutations, increased BCR-ABL expression, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40c876b351459425198e4bff6f18632
https://doi.org/10.3109/10428194.2011.591013

Zobrazit plný text záznamu

Plný text ve formátu HTML

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

Autor: Brad Sullivan, John V. Reynolds, Haley Altamura, Alexandra L. Yeoman, Jasmina Georgievski, John F. Seymour, Mark P. Hertzberg, David T Yeung, Chani Field, Timothy P. Hughes, Bronte A. Jamison, Stuart Phillis, Jodi Prime, David M. Ross, Nancy Briggs, Susan Branford

Publikováno v: Blood. 121(19)

Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML) can maintain remission after discontinuation of imatinib. A prerequisite is stable, undetectable BCR-ABL1. It is not known how many patients achieve this response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708466f073d74972a3e73879b1c18eba
https://pubmed.ncbi.nlm.nih.gov/23515925

Zobrazit plný text záznamu

Chronic myelogenous leukemia: monitoring response to therapy

Autor: Jodi Prime, Susan Branford

Publikováno v: Current hematologic malignancy reports. 6(2)

Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df911ba8d1e0d79099322cfcab8c8033
https://pubmed.ncbi.nlm.nih.gov/21360071

Zobrazit plný text záznamu

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML

Autor: David T Yeung, Jodi Prime, Brad Sullivan, Alexandra L. Yeoman, Susan Branford, Jasmina Georgievski, David M. Ross, Chani Field, Stuart Phillis, Timothy P. Hughes, Bronte A. Jamison, Haley Altamura

Publikováno v: Blood. 120:165-165

Abstract 165 Introduction. The opportunity to discontinue kinase inhibitor therapy while maintaining a deep remission is desirable for many CML patients. Despite good responses to imatinib for most patients, treatment related side effects remain prob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42bb63a4948448421ce0e2dbc5b7739c
https://doi.org/10.1182/blood.v120.21.165.165

Zobrazit plný text záznamu

Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance

Autor: Timothy P. Hughes, Jodi Prime, Susan Branford, David T Yeung, David M. Ross

Publikováno v: Blood. 118:113-113

Abstract 113 Introduction. Adherence to therapy is known to be a critical factor for achieving an optimal imatinib (IM) response, and non-adherence is likely to be a cause of loss of response. In the absence of a biological marker of resistance, such

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c744adadb08ae924d9afa2b41edcb871
https://doi.org/10.1182/blood.v118.21.113.113

Zobrazit plný text záznamu

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression

Autor: Jodi Prime, Carine Tang, Dale B. Watkins, Timothy P. Hughes, Deborah L. White, Lisa Schafranek, Wendy T Parker

Publikováno v: Blood. 116:3383-3383

Abstract 3383 There are three currently identified secondary resistance mechanisms observed in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs). These include overexpression of drug-efflux proteins (ABCB1 and ABCG2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db5b8bff22e98549e6bc9a112addc1d0
https://doi.org/10.1182/blood.v116.21.3383.3383

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání